Public Health
Insights on disease prevention and control, health promotion and education, environmental health and health equity and social justice.
Assessing strategies for mitigating infectious diseases
Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.
Watch the webinar: An introduction to infectious disease modelling
In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.
Antimicrobial resistance
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.
Fortifying vaccines: Preparation and prevention against future infectious disease epidemics
This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future.
The evolution of HIV treatments
HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
COVID-19 vaccines: Post-authorisation safety surveillance
This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.
.png?crop=yes&w=982&h=600&a=938,0&itok=-2rh_aOe "11828-005-Front-Page-Banner_Subpage-banner_1-(1)"){kind=icon}
Diversity and inclusion in clinical trials
Examining how the field of clinical research currently approaches diversity and inclusion gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.
Public Health media and blogs
-
Media article: Drug development practices to improve public health policy
Dr Andrew Garrett explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres.
-
Blog: mRNA vaccines from COVID-19 to HIV
How one virus accelerated vaccine research, spurring innovation and hope for a cure in another
-
Media article: BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
Blog: HIV Africa
Blog about HIV in Sub-Saharan Africa.
-
Blog: Bringing an invisible battle to the forefront: How to better design military-related TBI clinical trials
A form of acquired brain injury that occurs when trauma causes damage to the brain, TBI has become increasingly apparent in military personnel.
Science-led. Mission driven.
At ICON, our dedicated Government and Public Health Solutions team have been advancing the future of global health for over 30 years. Discover more about their work with US Government and NGOs.